Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
173 pending office actions • 64 clients • 160 examiners • 83 art units • 0 of 173 (0%) have an AI response strategy ready
Riverside Law LLP has 176 pending office actions in Biotechnology & Pharmaceuticals and 4526 career applications. Its resolved allowance rate is 80.94%, indicating that allowance was achieved in a substantial portion of resolved matters, while other outcomes form a significant part of the record.
The firm averages 4.11 office actions per allowance. This indicates a prosecution process in which allowed matters commonly require repeated examiner interaction. The substantial pending docket adds an important workload consideration for practitioners. Taken together, the figures support evaluation of a large biotechnology and pharmaceutical practice where application experience is broad but allowance may require sustained office-action strategy.
Based on the USPTO statutory response window for each pending office action. 62 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 62 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 24 (14%) |
| §103 only | 40 (23%) |
| §102 only | 3 (2%) |
| §112 only | 16 (9%) |
| Double-patenting only | 3 (2%) |
| Double-patenting + other | 12 (7%) |
| Multi-statute (no §101) | 73 (42%) |
| No statute on record | 1 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOWLER, DANIEL WAYNE | 2 | 72.6% | +12.0% |
| GRIZER, CASSANDRA SENN | 2 | 70.0% | +48.0% |
| WILSON, KAYLEE R | 2 | 62.0% | +53.5% |
| ALLEN, MICHAEL D | 2 | 31.9% | +48.8% |
| SIFFORD, JEFFREY MARK | 2 | 55.1% | +32.8% |
| YOON, CHANEL J | 2 | 55.5% | +39.3% |
| ALLEN, MARIANNE P | 2 | 60.1% | +18.4% |
| LANNU, JOSHUA DARYL DEANON | 2 | 82.2% | +24.1% |
| SCHUBERG, LAURA J | 2 | 23.6% | +37.0% |
| VOORHEES, CATHERINE M | 2 | 83.6% | +13.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17518243 | DEVICE AND METHOD FOR UNATTENDED TREATMENT OF A PATIENT | VOORHEES, CATHERINE M | 71d overdue |
| 18322109 | CONTOUR ELECTROCORTICOGRAPHY (ECoG) ARRAY | LANNU, JOSHUA DARYL DEANON | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17907697 | Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19 | ROSSI, JULIA ANNE LORRAIN | 167d overdue |
| 18064482 | LARGE AND SMALL T ANTIGENS OF MERKEL CELL POLYOMAVIRUS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | FOLEY, SHANON A | 138d overdue |
| 18458214 | Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders | ALLEN, MARIANNE P | 104d overdue |
| 18248166 | METHOD FOR DETERMINING WHETHER OR NOT VIRUS-NEUTRALIZING ANTIBODIES ARE PRESENT AND IN VITRO METHOD FOR SCREENING COMPOUNDS FOR THEIR ABILITY TO NEUTRALIZE A VIRUS | GRIZER, CASSANDRA SENN | 84d overdue |
| 18001116 | CORONAVIRUS DISEASE 2019 (COVID-19) COMBINATION VACCINE | ALLEN, MICHAEL D | 79d overdue |
| 17488409 | DIGITALLY COACHED SPIROMETRY SYSTEM AND METHOD | CATINA, MICHAEL ANTHONY | 66d overdue |
| 19067406 | Doped Organic Semiconductors and Methods of Making the Same | NGUYEN, HAIDUNG D | 45d overdue |
| 18040515 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE RELEASE SYNDROME | PIHONAK, SARAH | 45d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18458214 | Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders | ALLEN, MARIANNE P | 104d overdue |
| 18248166 | METHOD FOR DETERMINING WHETHER OR NOT VIRUS-NEUTRALIZING ANTIBODIES ARE PRESENT AND IN VITRO METHOD FOR SCREENING COMPOUNDS FOR THEIR ABILITY TO NEUTRALIZE A VIRUS | GRIZER, CASSANDRA SENN | 84d overdue |
| 18001116 | CORONAVIRUS DISEASE 2019 (COVID-19) COMBINATION VACCINE | ALLEN, MICHAEL D | 79d overdue |
| 17518243 | DEVICE AND METHOD FOR UNATTENDED TREATMENT OF A PATIENT | VOORHEES, CATHERINE M | 71d overdue |
| 18006321 | LIQUID CRYSTAL SCAFFOLDS AND USE THEREOF | SCHUBERG, LAURA J | 37d overdue |
| 18194781 | METHODS FOR ISOLATING AND CULTURING LIVING CELLS USING METHOD OF PERMEABILIZING CELL MEMBRANE | SCHUBERG, LAURA J | 13d |
| 18002125 | Containment, Treatment, and Removal of Aerosolized Viral Contamination | LANNU, JOSHUA DARYL DEANON | 20d |
| 18184813 | DEVICE AND METHOD FOR UNATTENDED TREATMENT OF A PATIENT | VOORHEES, CATHERINE M | 27d |
| Art Unit | Apps |
|---|---|
| 3791 | 12 |
| 3792 | 7 |
| 3794 | 5 |
| 1672 | 5 |
| 1671 | 5 |
| 1631 | 5 |
| 1638 | 5 |
| 1647 | 5 |
| 3796 | 4 |
| 3700 | 4 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19381766 | Apparatus, Method, and System for Medical Imaging and Characterization of Tissue Structure | UNIVERSITY OF ROCHESTER | EDUN, DEAN NAWAAB | 3797 | §102§103§112 | Non-Final OA | — | Pending | Nov 06, 2025 |
| 19260994 | APPARATUS, SYSTEM AND METHOD OF OPERATING AN ADDITIVE MANUFACTURING NOZZLE | 3D Print Innovations, LLC | LIU, XUE H | 1742 | §102§103 | Non-Final OA | — | Pending | Jul 07, 2025 |
| 19196969 | DRYING EQUIPMENT USAGE AUDIT SYSTEM AND METHOD | Novadata Solutions LLC | JARRETT, SCOTT L | 3625 | §101§102 | Non-Final OA | — | Pending | May 02, 2025 |
| 19175271 | INTRACAVITARY, PHYSIOLOGICAL AUGMENTATION DEVICE AND METHOD | Yale University | SAHAND, SANA | 3796 | §102§103§112 | Non-Final OA | — | Pending | Apr 10, 2025 |
| 19114136 | SYSTEMS AND METHODS FOR WAFER INSPECTION AND SEGMENTED TOTAGRAPHY | Wavefront Analysis Systems LLC | LEE, SHUN K | 2884 | §103§112 | Non-Final OA | — | Pending | Mar 21, 2025 |
| 19077565 | INTRACARDIAC DEVICE | Yale University | MOSS, JAMES R | 3792 | §103§112DP | Non-Final OA | — | Pending | Mar 12, 2025 |
| 19067406 | Doped Organic Semiconductors and Methods of Making the Same | New York University | NGUYEN, HAIDUNG D | 1761 | §102§103§112 | Final Rejection | 45d overdue | Pending | Feb 28, 2025 |
| 19023127 | PULSED FIELD ABLATION DEVICE AND METHOD | Btl Medical Development A.S. | FOWLER, DANIEL WAYNE | 3794 | §103§112 | Non-Final OA | — | Pending | Jan 15, 2025 |
| 19014404 | SYSTEM AND METHOD FOR ASSESSMENT AND REHABILITATION OF BALANCE IMPAIRMENT USING VIRTUAL REALITY | Temple University-Of The Commonwealth System Of Higher Education | OGLES, MATTHEW ERIC | 3791 | §103§112 | Non-Final OA | — | Pending | Jan 09, 2025 |
| 18987506 | WEARABLE ELECTRICAL STIMULATION DEVICE AND METHOD | Commonspirit Health | STEINBERG, AMANDA L | §103 | Non-Final OA | — | Pending | Dec 19, 2024 | |
| 18985963 | APPARATUS, SYSTEM AND METHOD FOR AN ADDITIVE MANUFACTURING PRINT HEAD | 3D Print Innovations, LLC | MCKANE, ELIZABETH L | 3991 | §103 | Final Rejection | 48d | Pending | Dec 18, 2024 |
| 18981897 | SYSTEM AND METHOD FOR MODIFYING A LIVING ENVIRONMENT TO ASSIST IN FALL PREVENTION | Myraina, LLC | CHEN, PATRICK C | 2836 | §103§112 | Non-Final OA | — | Pending | Dec 16, 2024 |
| 18975545 | Use of short chain fatty acids for the treatment and prevention of diseases and disorders | Temple University-Of The Commonwealth System Of Higher Education | ALLEY, GENEVIEVE S | 1617 | §103DP | Non-Final OA | — | Pending | Dec 10, 2024 |
| 18966538 | ARAMID REINFORCED INSTANT FLEXIBLE CAST STRIPS | Matscitechno Licensing Company | FISHER, VICTORIA HICKS | 3786 | §103 | Final Rejection | — | Pending | Dec 03, 2024 |
| 18868003 | DEVICE AND METHOD FOR TREATMENT OF PART OF A HUMAN BODY | Btl Medical Solutions A.S. | FOWLER, DANIEL WAYNE | 3794 | §102§103§112 | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18940457 | SYSTEM AND METHOD FOR ASSESSING INTRACRANIAL ANEURYSMS | New York University | NEWTON, CHAD A | 3681 | §101§103 | Final Rejection | — | Pending | Nov 07, 2024 |
| 18939033 | SYSTEM AND METHOD FOR TETHERED UNMANNED AERIAL VEHICLE TAKEOFF, LANDING, AND STORAGE | Dragonfly Pictures, Inc. | MCFALL, NICHOLAS A | 3644 | §102§103§112 | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18860838 | AN EFFICIENT APPROACH TO OPTIMAL EXPERIMENTAL DESIGN FOR MAGNETIC RESONANCE FINGERPRINTING WITH B-SPLINES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | TCHATCHOUANG, CARL F.R. | 2858 | §101§112 | Final Rejection | — | Pending | Oct 28, 2024 |
| 18856345 | STABILIZED SPIKE PROTEIN AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | Daniel Kulp | GRIZER, CASSANDRA SENN | 1672 | §112 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18904575 | Compositions and Methods for Targeting Lipid Nanoparticle Therapeutics to Stem Cells | The Trustees of the University of Pennsylvania | WESTERBERG, NISSA M | 1618 | §103DP | Final Rejection | 18d overdue | Pending | Oct 02, 2024 |
| 18852059 | COMPACT SCALABLE DISSOLVED OXYGEN SENSOR | Yale University | TRAN, VIVIAN AILINH | 1794 | §103§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18848241 | DEVICES AND METHODS FOR RAPID BIOSENSING | New York University | SANGHERA, JAS A | 2852 | §102§103§112 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18820570 | PULSED FIELD ABLATION DEVICE AND METHOD | Btl Medical Development A.S. | PEFFLEY, MICHAEL F | 3794 | §102§103 | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18815038 | Discrete Microenvironment Chamber | New York University | HUANG, MICKEY NMN | 1758 | §102§103 | Final Rejection | — | Pending | Aug 26, 2024 |
| 18814421 | SWITCHING OF PERPENDICULARLY MAGNETIZED NANOMAGNETS WITH SPIN-ORBIT TORQUES IN THE ABSENCE OF EXTERNAL MAGNETIC FIELDS | UNIVERSITY OF ROCHESTER | NGUYEN, VAN THU T | 2824 | §102§103 | Final Rejection | 15d | Pending | Aug 23, 2024 |
| 18793238 | METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASE | Temple University-Of The Commonwealth System Of Higher Education | ROBINSON, MIKHAIL O'DONNEL | 1627 | §102§103 | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18784215 | DEVICE, SYSTEM, AND METHOD FOR NEUROMODULATION | Mayo Foundation for Medical Education and Research | PRUITT, HALEY NICOLE | 3796 | §103 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18783229 | AESTHETIC METHOD OF BIOLOGICAL STRUCTURE TREATMENT BY MAGNETIC FIELD | Btl Medical Solutions A.S. | WILSON, KAYLEE R | 3700 | §103§112Other | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18728224 | Quantized Bistable Resistively-coupled Ising Machine | UNIVERSITY OF ROCHESTER | KINKEAD, ARNOLD M | 2849 | §102Other | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18768701 | Foot and Mouth Disease Virus (FMDV) Consensus Proteins, Coding Sequences Therefor and Vaccines Made Therefrom | Inovio Pharmaceuticals, Inc. | CHESTNUT, BARRY A | 1672 | §101§103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18765882 | OPTIMIZED NUCLEIC ACID ANTIBODY CONSTRUCTS | Inovio Pharmaceuticals, Inc. | ALLEN, MICHAEL D | 1671 | §112 | Non-Final OA | — | Pending | Jul 08, 2024 |
| 18745131 | SYSTEM AND METHOD FOR BREAST CANCER DETECTION USING CO-LOCALIZED ULTRASOUND-MAMMOGRAPHY | Thomas Jefferson University | FERNANDEZ, KATHERINE L | 3798 | §103§112 | Final Rejection | 14d | Pending | Jun 17, 2024 |
| 18740678 | Method and device for microwave treatment | Btl Healthcare Technologies A.S. | SHOULDERS, ANNIE LEE | 3794 | §102§103 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18737066 | PROTOCOL GENERATING TISSUE SPECIFIC ENDOTHELIAL CELL LINE, NAMED LIOVECS (LUNG TISSUE IPSC ORIGIN VESSEL ORGANOID ENDOTHELIAL CELL) AND BIOVECS (BLOOD VESSEL STEM CELL IPSC ORIGIN VESSEL ORGANOID ENDOTHELIAL CELLS) | The Catholic University Of Korea Industry-Academic Cooperation Foundation | KIM, TAEYOON | 1631 | §103 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18715012 | HUMAN CORTICAL ORGANOIDS WITH ENGINEERED MICROGLIA-LIKE CELLS | Yale University | ROGERS, ERIC JASON | 1638 | §103§112 | Non-Final OA | — | Pending | May 30, 2024 |
| 18712889 | METHOD FOR PRODUCING CULTURED MEAT BY UTILIZING FBS SUBSTITUTE DERIVED FROM BUTCHERY BY-PRODUCTS | Chung-Ang University Industry-Academic Cooperation Foundation | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Non-Final OA | — | Pending | May 23, 2024 |
| 18659711 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLON CANCER INCLUDING EXTRACELLULAR VESICLES LOADED WITH MACC1 INHIBITOR AS ACTIVE INGREDIENT | The Catholic University Of Korea Industry-Academic Cooperation Foundation | TATGE, LEXUS MARC | 1637 | §112 | Non-Final OA | — | Pending | May 09, 2024 |
| 18650511 | Reverse Osmosis Systems and Methods | Colorado School Of Mines | ORME, PATRICK JAMES | 1779 | §102§103§112 | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18647191 | METHOD FOR PRODUCING VASCULARIZED RESPIRATORY ORGANOID FUSED WITH BLOOD VESSEL ORGANOID | The Catholic University Of Korea Industry-Academic Cooperation Foundation | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18705288 | NOROVIRUS VACCINE AND METHODS OF USE | The Trustees of the University of Pennsylvania | CHONG, KIMBERLY | 1636 | §102§103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18704129 | COMPOSITION COMPRISING BOTULINUM-DERIVED PEPTIDE FOR PAIN RELIEF | BPMED CO., LTD. | GOUGH, TIFFANY MAUREEN | 1651 | §102 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18703591 | COMPOSITION FOR AMELIORATING HAIR LOSS COMPRISING BOTULINUM-DERIVED PEPTIDE | BPMED CO., LTD. | IANNUZO, NATALIE NMN | 1653 | §103 | Final Rejection | 72d | Pending | Apr 22, 2024 |
| 18640327 | PREDICTIVE MAINTENANCE ALGORITHM PROVIDING METHOD FOR BUS MAINTENANCE PRIORITY DETERMINATION | Korea Transportation Safety Authority | CLARE, MARK C | 3628 | §101 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18628195 | AUTOMATED OPTICAL MICROPIPETTE ELECTRODE GUIDANCE SYSTEM AND METHOD | Arizona Board of Regents | XU, XIAOYUN | 1797 | §103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18699081 | Novel Immune Cell Engagers For Immunotherapy | The Wistar Institute | GURLEY, JAMI MICHELLE | 1647 | §102§103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18621914 | BIOMARKERS FOR AMYOTROPHIC LATERAL SCLEROSIS STRATIFICATION | Arizona Board of Regents | SALMON, KATHERINE D | 1682 | §101§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18609070 | Use of Short Chain Fatty Acids in Cancer Prevention | Temple University-Of The Commonwealth System Of Higher Education | PYLA, EVELYN Y | 1633 | §103 | Final Rejection | 2d overdue | Pending | Mar 19, 2024 |
| 18690480 | SYSTEM AND METHOD FOR STEREOSCOPIC IMAGE GENERATION | New York University | BRUTUS, JOEL F | 3797 | §103 | Final Rejection | 8d overdue | Pending | Mar 08, 2024 |
| 18593283 | ANGLE-ADJUSTABLE RATCHET TOOL | Thomas Jefferson University | CHUKWURAH, NATHANIEL C | 3731 | §103 | Final Rejection | — | Pending | Mar 01, 2024 |
| 18588643 | MAGE-A VACCINES AND METHODS OF TREATMENT USING THE SAME | The Wistar Institute | EDGINGTONGIORDANO, FRANCESCA | 1643 | §101§102§112Other | Non-Final OA | 37d overdue | Pending | Feb 27, 2024 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial80.9% of resolved applications prosecuted by Riverside Law LLP were allowed, across 4,526 applications in USPTO records.
4.11 office actions per allowed application on average.
173 pending office actions as of October 2026, for 64 clients, before 160 examiners in 83 art units.
